Table 3.

Clinical outcome and functional results at date last seen

#	Time to AS resolution (months)		Follow-up time (months)			Treatment-related complications		Other complications		Visual acuities and OCT-assessed foveal microanatomy
	First event	Second event	From first ICC	Tumour-free aqueous humour from last ICC	Tumour-free globe from last rb treatment	Type	Management	Type	Management	Fovea	BCVA Distance	BCVA Near
1	3.0	1.8	119	111	111	CT	L+IOL	0	0	Intact	1.6	1.25
2	1.9	–	92	91	86	HI/IA/PS	0	0	0	Altered	0.10	0.10
3	1.2	–	66	65	64	IA/CT	L+IOL	RRD	SB/PPV+silicone	Intact	0.8	0.8
4	0.8	–	67	*	*	0	0	0	0	*
5	2.0	–	71	68	68	CT	L+IOL	0	0	Altered	0.5	0.5
6	0.7	2.8	64	58	33	PS/IA/CT	L+IOL	0	0	Destroyed	0.06	0.10
7	0.7	–	54	*	*	0	0	0	0	*
8	1.7	–	61	56	55	CT	L+IOL	0	0	Altered	0.5	0.5
9	3.2	–	48	45	45	CT	L+IOL	0	0	Altered	0.03	0.03
10	0.8	–	41	40	24	CT	L+IOL	RRD	Endolaser/PPV+silicone	Intact	1.0	1.0
11	1.4	–	39	38	28	CT	L+IOL	0	0	Intact	1.25	1.0
12	0.5	–	38	37	29	IA	0	0	0	Destroyed	0.06	0.06
13	1.0	–	33	32	24	CT	L+IOL	0	0	Altered	0.5	0.4
14	1.6	1.1	33	13	13	IA / CT	L+IOL	TRD	SB/retinotomy/PPV+silicone	Altered	0.13	0.13
15	1.0	–	27	26	26	0	0	0	0	Intact	0.8	1.0
16	0.2	–	27	27	26	0	0	0	0	Intact	0.8	0.8
17	0.2	–	29	*	*	CT	L+IOL	0	0	*
18	0.7	–	25	25	2	0	0	0	0	Intact	1.0	1.0
19	0.2	–	19	18	18	0	0	0	0	Destroyed	No LP
20	1.2	–	16	15	15	0	0	0	0	Intact	1.25	1.0

*Enucleated eye.

AS, aqueous seeding; BCVA, best-corrected visual acuity; CT, cataract; HI, heterochromia iridis; IA, iris atrophy; ICC, intracameral chemotherapy; L+IOL, lensectomy+intraocular lens; LP, light perception; OCT, optical coherence tomography; PPV, pars plana vitrectomy; PS, posterior synechia; rb, retinoblastoma; RRD, rhegmatogenous retinal detachment; SB, scleral buckle; TRD, tractional retinal detachment.